Long-term azithromycin treatment reduced exacerbations in adults with persistent symptomatic asthma in the AMAZES trial (Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235) [1]. However, response to treatment was variable between participants and the characteristics of those who experience most clinical benefit have not been determined. The inability to define a specific population who are more responsive limits the ability to personalise this therapy, which is the goal for airways disease management [2]. With recent studies identifying airway Haemophilus influenzae colonisation as a candidate marker for asthma subgrouping [3, 4], we assessed whether H. influenzae abundance, measured using quantitative PCR (qPCR) [5, 6], predicted the ability of azithromycin therapy to reduce the incidence of acute asthma exacerbations. Sputum Haemophilus influenzae load predicts response to azithromycin in adults with persistent uncontrolled asthma: secondary findings from the AMAZES trial The following investigators constitute the AMAZES Investigators Group: Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Christine Jenkins, Matthew J. Peters, Melissa Baraket and Guy B. Marks.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2020) studied this question.